AUG 07, 2018 10:00 PM PDT

Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association

WRITTEN BY: Mauri Brueggeman

Hypermethylation has been documented in some myeloid disorders including myelodysplastic syndrome (MDS) and in renal cell carcinoma (RCC).  A group at the Mayo Clinic noticed the epigenetic marking patterns between these vastly different conditions and wondered if there was a connection.  The group found that there was a strong association.

Epigenetics, as a field, is being embraced and has been studied for numerous years.  The term “epigenetics” has been around for nearly three quarters of a century, being coined in 1942 by a British developmental biologist named C.H. Waddington.  Some of the genetic underpinnings of heritable changes in gene expression are known but much, as of yet, is less well understood.  Studies have shown that the modification of gene expression results in a variety of conditions that can be congenital or acquired.  The most studied epigenetic change is DNA methylation whereby a methyl group is covalently transferred to the C-5 position of the cytosine ring within a strand of DNA.  DNA methylation can occur within any area of the genome on any given cytosine in mammals; however, most of the methylation takes place in CpG dinucleotide regions which are sequences of DNA with a cytosine (C) nucleotide followed by guanine (G) molecule connected by a phosphodiester bond (“p”).  

In RCC and some myeloid cancers, there is atypical DNA hypermethylation in those CpG regions within tumor suppressor gene promotor regions which inactivate many cellular pathways which lead to cancer.  The researchers at the Mayo Clinic used an explorer database and the Dusseldorf MDS registry to identify patients with a history of both RCC and hematologic malignancies including MDS.  They analyzed clinical features and long-term outcomes; 59 patients were identified as having both RCC and a myeloid malignancy history.  Out of the total, 38 of 59 patients had MDS diagnoses; there was a predominant male to female ratio with a nearly 4.5 times likelihood of a male versus female developing a myeloid malignancy after RCC.  The researchers documented a strong association between RCC and MDS with RCC being the initial diagnosis at a median age of 64 with further development of a MDS in their mid-seventies.  The group concluded that patients with a history of RCC appear to have a significant risk of a MDS emerging later in life compared to the overall population.

Sources: Clinical Genitourinary Cancer,  Cold Spring Harbor Perspectives, Environmental Health Perspectives, Genes and Cancer, Oncogene,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
NOV 25, 2019
Cell & Molecular Biology
NOV 25, 2019
Linking Intestinal Stem Cells with Increased Cancer Risk From a High-Fat Diet
The work, which used a mouse model, links stem cell activity with cellular fat consumption in a new way....
NOV 29, 2019
Immunology
NOV 29, 2019
Protecting Killer Immune Cells from Themselves
Destroying human cells compromised by viruses and cancer is the name of the game for so-called “killer” cells of the immune system. They employ...
DEC 21, 2019
Cancer
DEC 21, 2019
Processed meats containing nitrites linked to cancer
Since 2015, when the World Health Organization (WHO) classified processed meats as Group 1 carcinogens, science has supported the idea that these foods pos...
JAN 09, 2020
Drug Discovery & Development
JAN 09, 2020
Can Cancer Drugs Treat Lung Damage?
Can therapeutics used in the treatment of cancer be a breakthrough for pulmonary disease? Specifically, chronic obstructive pulmonary disease (COPD)? &ldqu...
JAN 13, 2020
Cell & Molecular Biology
JAN 13, 2020
Disrupting Leukemia's Deadly Reliance on Vitamin B6
Acute Myeloid Leukemia is a cancer of the blood that starts in the bone marrow, where the stem cells that produce blood cells reside, and rapidly moves to the blood....
JAN 20, 2020
Cancer
JAN 20, 2020
Did you know these non-cancer drugs can also fight cancer?
A study from MIT. Harvard and the Dana-Farber Cancer Institute has concluded that almost 50 existing non-oncological drugs have anti-cancer properties capa...
Loading Comments...